We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Standigm

News List

Standigm Secures $10 M From Pavilion Capital to Accelerate Its Global Competitiveness firstwordpharma
July 07, 2021
Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that they have secured a $10 million investment from Pavilion Capital, a Singapore-based investment institution.
Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership prnasia
January 11, 2021
Standigm Inc. announced that they had successfully found a new arthritis indication for an FDA-approved drug and filed a patent. This is the first successful result of their open innovation partnership, formed in July 2019.
Standigm raises $11.5M in Series B Round biospectrumasia
April 02, 2019
Standigm will use the funds to scale the AI technology platforms and advance its drug discovery pipelines toward license-out
Standigm, an AI based Drug Discovery Company, Launched AI Drug Discovery Services Publicly at Bio-Eu prnasia
November 14, 2017
CEO and cofounder of Standigm, Jinhan Kim, is introducing the new AI based drug discovery services, ‘Expander’ and ‘Hunter’ at the Bio-Europe 2017 in Berlin, Germany. Photo credit: Standigm